- Home
- BNRG vs QNRX Comparison
BNRG vs QNRX Comparison
Compare BNRG & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNRG
- QNRX
- Stock Information
- Founded
- BNRG 2012
- QNRX 2018
- Country
- BNRG Israel
- QNRX United States
- Employees
- BNRG N/A
- QNRX N/A
- Industry
- BNRG
- QNRX Medical/Dental Instruments
- Sector
- BNRG
- QNRX Health Care
- Exchange
- BNRG Nasdaq
- QNRX Nasdaq
- Market Cap
- BNRG 5.2M
- QNRX 5.5M
- IPO Year
- BNRG 2022
- QNRX N/A
- Fundamental
- Price
- BNRG $2.10
- QNRX $8.17
- Analyst Decision
- BNRG
- QNRX
- Analyst Count
- BNRG 0
- QNRX 0
- Target Price
- BNRG N/A
- QNRX N/A
- AVG Volume (30 Days)
- BNRG 659.0K
- QNRX 3.3K
- Earning Date
- BNRG 08-29-2025
- QNRX 08-07-2025
- Dividend Yield
- BNRG N/A
- QNRX N/A
- EPS Growth
- BNRG N/A
- QNRX N/A
- EPS
- BNRG N/A
- QNRX N/A
- Revenue
- BNRG N/A
- QNRX N/A
- Revenue This Year
- BNRG N/A
- QNRX N/A
- Revenue Next Year
- BNRG N/A
- QNRX N/A
- P/E Ratio
- BNRG N/A
- QNRX N/A
- Revenue Growth
- BNRG N/A
- QNRX N/A
- 52 Week Low
- BNRG $1.78
- QNRX $5.01
- 52 Week High
- BNRG $15.30
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- BNRG 39.74
- QNRX 40.76
- Support Level
- BNRG $1.95
- QNRX $8.20
- Resistance Level
- BNRG $2.15
- QNRX $8.69
- Average True Range (ATR)
- BNRG 0.15
- QNRX 0.36
- MACD
- BNRG 0.04
- QNRX -0.10
- Stochastic Oscillator
- BNRG 29.52
- QNRX 0.00
About BNRG Brenmiller Energy Ltd
Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.